Roivant Sciences insider filing reveals 10.3M-share option stake
Rhea-AI Filing Summary
Roivant Sciences (ROIV) – Form 3. President & Vant Chair Frank Torti has filed his initial beneficial-ownership report covering 10.27 million common shares underlying stock options. Exercise prices range from $3.85 to $13.07 with expiry dates between 2028-2032. The largest tranche is 6.03 million options at $3.85 that vest 25% on 20-Apr-2023 and monthly thereafter; all other grants are already fully vested. No non-derivative share holdings were disclosed. The filing confirms Torti’s officer status and records his equity incentives for Section 16 compliance.
Positive
- Management alignment: Large option position incentivises President Frank Torti to drive share-price appreciation.
Negative
- Potential dilution: Exercise of 10.27 m options could increase the share count, notably the low-priced $3.85 tranche.
Insights
TL;DR: Routine Form 3; 10.3 m options show alignment but limited dilution risk, net neutral for valuation.
The disclosure is procedural, establishing Frank Torti as a Section 16 insider. While the aggregate 10.27 m options represent a sizeable potential issuance, the weighted-average strike (≈$5.53, skewed by the $3.85 grant) sits above recent lows yet below historical highs, aligning management with share appreciation. No immediate share issuance or cash impact occurs, so near-term fundamentals are unchanged. Possible dilution—about 1.3% of current basic shares outstanding if fully exercised—remains a medium-term consideration. Overall, the filing is informational rather than catalytic.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
Footnotes (1)
- Reflects an award of stock options to purchase Common Shares that is fully vested. Reflects an award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date (except as otherwise provided in the award documentation).
